Activation of the alternate complement pathway in human serum by several bacterial components was compared. Peptidoglycan from group A streptococcal cell walls was the most active material, on a weight basis, followed by cell walls, protoplast membranes, and whole cells. The (6) showed that pneumococcal cell walls could inhibit phagocytosis and that this activity may be associated with the anticomplementary activity of mucopeptide (peptidoglycan). Bokisch (4) has shown that peptidoglycan extensively subjected to sonic treatment can activate complement in human serum. However, he failed to observe significant activation of the ACP.
The alternate complement pathway (ACP) can be activated by several microbial components. Lipopolysaccharide (LPS) from gramnegative bacterial cell walls is a well-known example (11) . Our understanding of the chemical structures from gram-positive bacteria responsible for activating the ACP is less precise. Tauber et al. (23) have demonstrated activation of the ACP in human serum by cytoplasmic membranes and cell walls from group A streptococci and several other gram-positive bacteria. Pneumococcal cell walls have also been reported to activate the ACP in guinea pig serum (24) . Dhingra et al. (6) showed that pneumococcal cell walls could inhibit phagocytosis and that this activity may be associated with the anticomplementary activity of mucopeptide (peptidoglycan). Bokisch (4) has shown that peptidoglycan extensively subjected to sonic treatment can activate complement in human serum. However, he failed to observe significant activation of the ACP.
Purified group A streptococcal cell walls consist of a peptidoglycan-polysaccharide complex that has been well characterized (14) . The group-specific carbohydrate moiety consists of a backbone of rhamnose with rhamnose side chains terminating with N-acetyl-glucosamine residues. The peptidoglycan moiety is made up of repeating units of the disaccharide N-acetylglucosamine-muramic acid, with the carboxyl group of muramic acid being substituted by either the tetrapeptide L-ala-D-glu-L-lys-D-ala or the pentapeptide L-ala-D-glu-L-lys-D-ala-D-ala (20) . In many instances there is a D-ala-D-ala dipeptide bridge between the free amino group of lysine and the C-terminal D-alanine of an adjacent peptide.
In this report we examine the capacity of streptococcal cell wall components and membranes to activate the ACP. The results provide definitive evidence that the peptidoglycan moiety of bacterial cell walls is a very effective activator or the ACP in human serum.
MATERIALS AND METHODS
Organisms. Group The partially purified cell walls, consisting primarily of the mucopeptide-mucopolysaccharide complex, were prepared as follows. Cell walls were suspended in PBS (10 mg/ml) and treated with 0.025% ribonuclease and deoxyribonuclease at 37°C for 4 h. They were washed once with PBS and treated with 0.25% trypsin at 37°C for 4 h. After washing three times with PBS and three times with deionized water, they were lyophilized. The rhamnose content is 30 to 35%, and the nitrogen content is about 6%. Group D cell walls were prepared in a similar manner except that they were heated to 62°C for 45 min to prevent autolysis.
The mucopeptide moiety was obtained by formamide extraction of partially purified cell walls as described by Krause and McCarty (15) . Cell walls were suspended in freshly distilled formamide (5 mg/ml) and heated with constant stirring for 1 h at 170°C. After cooling to 4°C for 2 h, the insoluble mucopeptide was sedimented at 35,000 x g for 30 min. This sediment was extracted five times in hot formamide, washed three times with deionized water, and dialyzed against water at 4°C for 24 h. After lyophilization, the product is a buff to tan powder, with a rhamnose content of 1 to 5% and a nitrogen content of 13%. The preparation used in this study had a rhamnose content of 4.2%. Peptidoglycans from C. violaceum and B. cereus were prepared by a phenol extraction procedure as described previously (1) . Cytoplasmic membranes were prepared from protoplasts from group A streptococcus as described (22 Two recent discoveries have made it possible to modify the kinetic method to measure activation of the ACP. This modification utilizes the fact that classical pathway function requires both Mg2e and Ca2", whereas activation of the ACP requires only Mg2e (9) .
By using ethylene glycol bis-amino tetraacetic acid (EGTA) buffer (Sigma Chemical Co.), which is a strong chelator of Ca2" but only weakly binds Mg2+, it is possible to selectively block classical pathway function while leaving the ACP intact. More recently it has been demonstrated by Platts-Mills and Ishizaka (17) that normal rabbit red cells are capable of activating the ACP in EGTA-buffered normal human serum. This report has been confirmed by Schreiber et al. (21) , and evidence suggests that rabbit red cells react with initiating factor of human serum.
The kinetic method has been modified to measure ACP activation by using EGTA with added Mg2" Whole blood was collected from New Zealand white rabbits directly into Alsever solution. Before use, the cells were washed three times in VBS-EDTA buffer, incubated at 37°C for 60 min in VBS-EDTA buffer, washed three times in VBS-EGTA-Mg buffer, and suspended in the same buffer. The red blood cell concentration was adjusted so that when 0.2 ml of rabbit red blood cells was added to 1.4 ml of VBS-EGTA-Mg buffer, the optical density was 0.7 at 700 nm.
Serum was collected from normal individuals by venipuncture. The blood was allowed to clot at room temperature for 1 h and at 0°C for 2 h. The clotted blood was then centrifuged at 2,000 rpm for 20 min in an IEC PR-2 refrigerated centrifuge. The Inhibition studies. N-acetyl glucosamine and Nacetyl muramic acid were obtained from Sigma Chemical Co. D-Alanyl-D-alanine was obtained from VegaFox, Tuscon, Ariz. Inhibition studies were performed as follows: 100 ,ug of N-acetyl-glucosamine, N-acetyl muramic acid, D-alanyl-D-alanine, or lysozyme-solubilized peptidoglycan in 0.1 ml of VBS-EGTA-Mg buffer was added to 0.1 ml of PBS containing 1 ,ug of peptidoglycan. VBS-EGTA-Mg buffer was added to make a final volume of 0.4 ml, and the mixture was incubated for 10 min at 37°C. One milliliter of human serum was then added, mixed, and incubated at 37°C for 60 min. The percent complement removed was measured as described under Complement assay. Controls consisted of peptidoglycan and inhibitors alone.
Electrophoresis. Goat anti-human C3 and goat anti-human factor B (C3PA) were obtained from Atlantic Antibody, Westbrook, Me. Cobra venom factor was obtained from Cordis Labs, Miami, Fla. EA were prepared as described by Rapp and Borsos (18) . Preceding electrophoresis, human serum was mixed with peptidoglycan or test material in the following manner. To 0.1 ml of test material was added 0.3 ml of VBS-EGTA-Mg buffer. One milliliter of a 1:3 dilution of human serum was added and mixed. The tubes were then incubated at 37°C for 60 min. The tubes were centrifuged, and the supernatant was used for electrophoresis. Conversion of C3-)C3i was examined by crossed immunoelectrophoresis according to the method of Laurrel (16) . Conversion of Factor B-43 was examined by immunoelectrophoresis as described by Scheidegger (19) . Results were compared with serum incubated without test material (negative control) and with serum incubated with cobra venom factor (positive control). Low concentrations of lysozyme enhanced ACP activation by peptidoglycan, whereas higher concentrations of lysozyme progressively destroyed activity (Fig. 1) . Although the enhancement is not statistically significant, increased activity has been consistently observed with several preparations of peptidoglycan and low concentrations of lysozyme. This indicates that complement activation is dependent upon the particle size of peptidoglycan. In our buffer system, the ACP was not activated by peptidoglycan suspensions which had been extensively degraded by lysozyme treatment. After treatment with lysozyme, there was no significant change in the capacity of group A cell walls to activate the ACP. In contrast, the ACP activity of group D cell walls was almost completely destroyed. It has previously been shown that group A streptococcal cell walls are very resistant to the lytic effects of lysozyme (12), whereas group D cell walls are readily lysed. As expected, endotoxin activity was not affected by lysozyme. The results also rule out the possibility that the cell walls and peptidoglycan are contaminated with endotoxin. Lysozyme alone does not activate the ACP (Fig. 1) .
RESULTS

Activation
To explore further the effects of particle size on activation of the ACP, peptidoglycan was fragmented mechanically rather than enzymatically. Peptidoglycan, group A streptococcal cell wall, and zymosan were sonically treated for from 1 to 180 min and tested for activation of the ACP. Analogous to the lysozyme treatment, there was enhancement of ACP activation with peptidoglycan preparations treated with up to 30 min of sonic treatment (Fig. 2) . Thereafter, ACP activation decreased, reaching a very low level after 180 min of sonic treatment. In contrast, group A streptococcal cell wall and zymosan, which are much more resistant to degradation by sonic treatment, showed only slight changes in their complement-activating ability.
Inhibition studies. We attempted to identify more precisely the structure of peptidoglycan which was responsible for activating the ACP. For this purpose, experiments were designed to detect blocking of ACP activation by purified components of peptidoglycan or peptidoglycan fragments solubilized by lysozyme. N-acetyl glucosamine, N-acetyl muramic acid, D-ala-D-ala, or lysozyme-solubilized peptidoglycan was mixed with peptidoglycan to detect inhibition of ACP activation. None of the compounds tested could inhibit complement activation by peptidoglycan, nor could they activate the ACP alone (Table  2) .
Immunoelectrophoresis. Evidence that the anti-complementary effect of peptidoglycan is the result of activation of the ACP rather than the classical pathway has depended thus far upon the activity proceeding in Ca2"-free conditions. It is possible that the peptidoglycan inhibits complement activity by binding to any component of the complement system. More direct evidence that peptidoglycan activates the ACP is provided by the demonstration of molecular alteration of C3 and factor B in Ca2"-free buffer (VBS-EGTA-Mg buffer). Crossed immunoelectrophoresis and immunoelectrophoresis were performed to demonstrate this conversion VOL. 19, 1978 on October (5) .
Bokisch (4) was the first to show that peptidoglycan isolated from both streptococci and Staphylococcus epidermidis was capable of activating complement. Because activation in normal serum was 40x that in C2-deficient serum, he concluded that complement activation by peptidoglycan proceeds almost entirely by the classical pathway. It seems probable that he did not detect significant activation of the ACP because he used peptidoglycan which was extensively solubilized by sonic treatment. We have demonstrated that extensive sonic treatment destroys the capacity of peptidoglycan to activate the ACP.
Activation of complement by either the classical or alternative pathway results in the generation of a wide spectrum of biological activities with the potential to elicit acute inflammation (7), modify the immune response (8), or initiate clotting (25) . It is important, therefore, to understand how bacterial products can activate the complement system directly without the requirement of antibody. Peptidoglycan is a cell wall polymer which occurs with minor chemical modification in almost all bacteria and is even more common than LPS. The potential influence of such material on protective or tissueinjuring processes mediated by complement may be significant.
